PMC:7293470 / 2052-2346 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T72","span":{"begin":38,"end":53},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T73","span":{"begin":54,"end":59},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T74","span":{"begin":125,"end":134},"obj":"UBERON:0002048"},{"id":"T75","span":{"begin":202,"end":208},"obj":"UBERON:0001005"},{"id":"T76","span":{"begin":209,"end":222},"obj":"UBERON:0001135"},{"id":"T77","span":{"begin":240,"end":250},"obj":"CHEBI:7034;CHEBI:7034"},{"id":"T78","span":{"begin":251,"end":271},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T49829","span":{"begin":38,"end":53},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T6948","span":{"begin":54,"end":59},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T52070","span":{"begin":125,"end":134},"obj":"UBERON:0002048"},{"id":"T37965","span":{"begin":202,"end":208},"obj":"UBERON:0001005"},{"id":"T82075","span":{"begin":209,"end":222},"obj":"UBERON:0001135"},{"id":"T68520","span":{"begin":240,"end":250},"obj":"CHEBI:7034;CHEBI:7034"},{"id":"T83831","span":{"begin":251,"end":271},"obj":"CHEBI:48561;CHEBI:48561"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T28","span":{"begin":216,"end":222},"obj":"Body_part"}],"attributes":[{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma32558"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T19","span":{"begin":91,"end":97},"obj":"Disease"},{"id":"T20","span":{"begin":105,"end":142},"obj":"Disease"},{"id":"T21","span":{"begin":125,"end":142},"obj":"Disease"},{"id":"T22","span":{"begin":144,"end":148},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":202,"end":208},"obj":"http://purl.obolibrary.org/obo/UBERON_0001005"},{"id":"T42","span":{"begin":216,"end":222},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T43","span":{"begin":216,"end":222},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T44","span":{"begin":216,"end":222},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T45","span":{"begin":216,"end":222},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T25","span":{"begin":54,"end":59},"obj":"Chemical"},{"id":"T26","span":{"begin":184,"end":192},"obj":"Chemical"},{"id":"T27","span":{"begin":260,"end":271},"obj":"Chemical"},{"id":"T28","span":{"begin":281,"end":283},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_48705"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_51083"},{"id":"A29","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_53453"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":91,"end":97},"obj":"Phenotype"},{"id":"T6","span":{"begin":105,"end":142},"obj":"Phenotype"},{"id":"T7","span":{"begin":144,"end":148},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0006510"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":294},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}

{"project":"LitCovid-PubTator","denotations":[{"id":"115","span":{"begin":181,"end":183},"obj":"Gene"},{"id":"130","span":{"begin":77,"end":85},"obj":"Species"},{"id":"136","span":{"begin":91,"end":97},"obj":"Disease"},{"id":"137","span":{"begin":105,"end":142},"obj":"Disease"},{"id":"138","span":{"begin":144,"end":148},"obj":"Disease"}],"attributes":[{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Gene:170589"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"Tax:9606"},{"id":"A136","pred":"tao:has_database_id","subj":"136","obj":"MESH:D001249"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:D029424"},{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"MESH:D029424"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors."}